A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(14 sites)

United States

Holy Name Medical Center /ID# 279017, Teaneck, New Jersey

Providence Portland Medical Center /ID# 277727, Portland, Oregon

Women & Infants Hospital /ID# 277930, Providence, Rhode Island

SCRI Oncology Partners /ID# 279733, Nashville, Tennessee

Texas Oncology-Austin North /ID# 279958, Austin, Texas

Next Virginia /ID# 279684, Fairfax, Virginia

Israel

Rabin Medical Center /ID# 279142, Petah Tikva, Central District

The Chaim Sheba Medical Center /ID# 275997, Ramat Gan, Tel Aviv

Tel Aviv Sourasky Medical Center /ID# 275852, Tel Aviv, Tel Aviv

Rambam Health Care Campus- Haifa /ID# 276004, Haifa

Shaare Zedek Medical Center /ID# 275854, Jerusalem

Japan

Hyogo Cancer Center /ID# 276940, Akashi-shi, Hyōgo

National Cancer Center Hospital /ID# 276715, Chuo-Ku, Tokyo

The Cancer Institute Hospital Of JFCR /ID# 276711, Koto-ku, Tokyo